Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Rivian Automotive, Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Rivian Automotive, Inc. trades at $12.91 (market cap $19.36B). The key difference: Rivian Automotive, Inc. is far larger — about 2.2× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Rivian Automotive, Inc. for 61 Days on average.
| KYMR | RIVN | |
|---|---|---|
Market Cap | $8.87B | $19.36B |
Volume | 779,107 | 16,483,640 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $22.45 |
52-Week Low | $55.80 | $12.50 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $8.26B | $19.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rivian (RIVN) trades at $13.37, down 1.26% as investors react to mixed Q3 2026 delivery results. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal improving revenue trends ($5.39B in 2025) but persistent losses (-$3.65B net income). Recent news highlights record vehicle deliveries of 19,248 units in Q3 2026 but disappointment over unchanged full-year guidance.
The outlook remains challenging with significant cash burn and negative margins, though analyst consensus suggests 26% upside to the $16.89 price target. Key risks include execution on R2 production ramp, competitive EV market pressures, and path to profitability. The stock trades near analyst low targets, reflecting cautious optimism about Rivian's scaling potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
